344 related articles for article (PubMed ID: 26989207)
1. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
2. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
3. Splenic marginal zone lymphoma.
Piris MA; Onaindía A; Mollejo M
Best Pract Res Clin Haematol; 2017; 30(1-2):56-64. PubMed ID: 28288718
[TBL] [Abstract][Full Text] [Related]
4. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.
Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ
Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260
[TBL] [Abstract][Full Text] [Related]
5. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
6. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
Parry M; Rose-Zerilli MJ; Ljungström V; Gibson J; Wang J; Walewska R; Parker H; Parker A; Davis Z; Gardiner A; McIver-Brown N; Kalpadakis C; Xochelli A; Anagnostopoulos A; Fazi C; de Castro DG; Dearden C; Pratt G; Rosenquist R; Ashton-Key M; Forconi F; Collins A; Ghia P; Matutes E; Pangalis G; Stamatopoulos K; Oscier D; Strefford JC
Clin Cancer Res; 2015 Sep; 21(18):4174-4183. PubMed ID: 25779943
[TBL] [Abstract][Full Text] [Related]
7. Clinical and diagnostic relevance of
Campos-Martín Y; Martínez N; Martínez-López A; Cereceda L; Casado F; Algara P; Oscier D; Menarguez FJ; García JF; Piris MA; Mollejo M
Haematologica; 2017 Aug; 102(8):e310-e312. PubMed ID: 28522570
[No Abstract] [Full Text] [Related]
8. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
Ponzoni M; Kanellis G; Pouliou E; Baliakas P; Scarfò L; Ferreri AJ; Doglioni C; Bikos V; Dagklis A; Anagnostopoulos A; Ghia P; Stamatopoulos K; Papadaki T
Am J Surg Pathol; 2012 Nov; 36(11):1609-18. PubMed ID: 23073320
[TBL] [Abstract][Full Text] [Related]
10. Splenic marginal zone lymphoma: disease features and management.
Matutes E
Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
[TBL] [Abstract][Full Text] [Related]
11. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract][Full Text] [Related]
12. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):371-378. PubMed ID: 29222281
[TBL] [Abstract][Full Text] [Related]
13. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
14. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
15. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
Bastidas-Mora G; Beà S; Navarro A; Gine E; Costa D; Delgado J; Baumann T; Magnano L; Rivas-Delgado A; Villamor N; Colomer D; Lopez-Guerra M; Rozman M; Balagué O; Martínez D; Baptista MJ; Escoda L; Alcoceba M; Blanes M; Climent F; Campo E; Wotherspoon A; López-Guillermo A; Matutes E
Br J Haematol; 2022 Jan; 196(1):146-155. PubMed ID: 34519021
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
17. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
Matutes E; Oscier D; Montalban C; Berger F; Callet-Bauchu E; Dogan A; Felman P; Franco V; Iannitto E; Mollejo M; Papadaki T; Remstein ED; Salar A; Solé F; Stamatopoulos K; Thieblemont C; Traverse-Glehen A; Wotherspoon A; Coiffier B; Piris MA
Leukemia; 2008 Mar; 22(3):487-95. PubMed ID: 18094718
[TBL] [Abstract][Full Text] [Related]
18. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
19. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
Rossi D; Trifonov V; Fangazio M; Bruscaggin A; Rasi S; Spina V; Monti S; Vaisitti T; Arruga F; Famà R; Ciardullo C; Greco M; Cresta S; Piranda D; Holmes A; Fabbri G; Messina M; Rinaldi A; Wang J; Agostinelli C; Piccaluga PP; Lucioni M; Tabbò F; Serra R; Franceschetti S; Deambrogi C; Daniele G; Gattei V; Marasca R; Facchetti F; Arcaini L; Inghirami G; Bertoni F; Pileri SA; Deaglio S; Foà R; Dalla-Favera R; Pasqualucci L; Rabadan R; Gaidano G
J Exp Med; 2012 Aug; 209(9):1537-51. PubMed ID: 22891273
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis of splenic and nodal marginal zone lymphoma.
Spina V; Rossi D
Best Pract Res Clin Haematol; 2017; 30(1-2):5-12. PubMed ID: 28288716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
